Payden & Rygel’s Labcorp LH Stock Holding History

Payden & Rygel’s Portfolio LH Stock Details LH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-43,592	Closed	-$8.59M	–	137
2023 Q1	$8.59M	Buy	+43,592	New	+$8.97M	0.51%	75

Other funds holding LH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Payden & Rygel's LH Position: Q2 2023 in Review

Payden & Rygel sold out of Labcorp (LH) in Q2 2023, closing a stake of 43,592 shares — an estimated $8.59M sold.

Payden & Rygel first reported a position in LH in Q1 2023 and held it in 1 quarter. The position peaked at $8.59M in Q1 2023. 932 funds tracked by Wall St. Rank hold LH as of Q2 2023.

Payden & Rygel reported no remaining Labcorp position as of Q2 2023 after selling out during the quarter.
Payden & Rygel sold 43,592 Labcorp shares in Q2 2023, an estimated $8.59M.
Payden & Rygel first reported a position in Labcorp in Q1 2023 and held it in 1 quarter.
Payden & Rygel's Labcorp position peaked at $8.59M in Q1 2023.
932 funds tracked by Wall St. Rank held Labcorp as of Q2 2023.

Based on Payden & Rygel's 13F filing for Q2 2023, filed 10 Aug 2023.